Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com

Research analysts at StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued to investors on Thursday. The firm set a “sell” rating on the stock.

Bio-Path Stock Down 15.6 %

Shares of NASDAQ BPTH opened at $1.14 on Thursday. Bio-Path has a one year low of $0.59 and a one year high of $12.00. The business’s fifty day moving average price is $0.89 and its 200-day moving average price is $1.25.

Institutional Trading of Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC bought a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.